Nitroxide Pharmaceutical Development for Age-Related Degeneration and Disease
November 2015
in “
Frontiers in Genetics
”
TLDR Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
The document discussed the development of nitroxide-based pharmaceuticals, particularly Tempol (TP), Tempol Hydroxylamine (TP-H), and OT-551, for treating age-related macular degeneration (AMD) and cardiovascular disease (CVD). These drugs aimed to reduce oxidative stress and inflammation, with clinical trials showing that OT-551 preserved visual acuity in over 200 AMD patients without adverse events over up to 2 years. OT-551 also showed promise in preventing radiation-induced skin burns and hair loss in brain cancer patients. Tempol improved microvascular function in smokers. The findings supported further development of nitroxide agents for various age-related and smoking-related conditions.